Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA internal medicine"
DOI: 10.1001/jamainternmed.2020.2759
Abstract: On March 23, 2020, the US Food and Drug Administration (FDA) granted Gilead Science an orphan drug designation for remdesivir to treat coronavirus disease 2019 (COVID-19), even though this status is usually reserved for drugs… read more here.
Keywords: drug; drug designation; orphan drug; designation remdesivir ... See more keywords